Electra Therapeutics, Inc.

Electra Therapeutics is a biotech company developing experimental medicines for immunology and cancer. The company's main focus is a drug called ELA026, a monoclonal antibody (a type of protein that targets specific cells in the body) designed to treat secondary hemophagocytic lymphohistiocytosis, a rare life-threatening condition where the immune system attacks the body's own cells. The company was founded in 2018 and is based in South San Francisco.